These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 34636551)
1. Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D Shaik AB; Boateng CA; Battiti FO; Bonifazi A; Cao J; Chen L; Chitsazi R; Ravi S; Lee KH; Shi L; Newman AH J Med Chem; 2021 Oct; 64(20):15313-15333. PubMed ID: 34636551 [TBL] [Abstract][Full Text] [Related]
2. Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism. Lane JR; Abramyan AM; Adhikari P; Keen AC; Lee KH; Sanchez J; Verma RK; Lim HD; Yano H; Javitch JA; Shi L Elife; 2020 Jan; 9():. PubMed ID: 31985399 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of bitopic arylpiperazinephenyl-1,2,4-oxadiazoles as preferential dopamine D3 receptor ligands. Cao Y; Min C; Acharya S; Kim KM; Cheon SH Bioorg Med Chem; 2016 Jan; 24(2):191-200. PubMed ID: 26707842 [TBL] [Abstract][Full Text] [Related]
4. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor. Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613 [TBL] [Abstract][Full Text] [Related]
5. Aromatic linker variations in novel dopamine D Di Biase C; Leitzbach L; Frank A; Zivkovic A; Stark H Arch Pharm (Weinheim); 2024 Aug; 357(8):e2400071. PubMed ID: 38736025 [TBL] [Abstract][Full Text] [Related]
6. Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment. Kumar V; Bonifazi A; Ellenberger MP; Keck TM; Pommier E; Rais R; Slusher BS; Gardner E; You ZB; Xi ZX; Newman AH J Med Chem; 2016 Aug; 59(16):7634-50. PubMed ID: 27508895 [TBL] [Abstract][Full Text] [Related]
7. Synthesis of bitopic ligands based on fallypride and evaluation of their affinity and selectivity towards dopamine D Tian GL; Hsieh CJ; Taylor M; Lee JY; Riad AA; Luedtke RR; Mach RH Eur J Med Chem; 2023 Dec; 261():115751. PubMed ID: 37688938 [TBL] [Abstract][Full Text] [Related]
8. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Chien EY; Liu W; Zhao Q; Katritch V; Han GW; Hanson MA; Shi L; Newman AH; Javitch JA; Cherezov V; Stevens RC Science; 2010 Nov; 330(6007):1091-5. PubMed ID: 21097933 [TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N-substituted 3-aryl-8-azabicyclo[3.2.1]octan-3-ol. Paul NM; Taylor M; Kumar R; Deschamps JR; Luedtke RR; Newman AH J Med Chem; 2008 Oct; 51(19):6095-109. PubMed ID: 18774793 [TBL] [Abstract][Full Text] [Related]
10. Factors Governing Selectivity of Dopamine Receptor Binding Compounds for D2R and D3R Subtypes. Hayatshahi HS; Luedtke RR; Taylor M; Chen PJ; Blass BE; Liu J J Chem Inf Model; 2021 Jun; 61(6):2829-2843. PubMed ID: 33988991 [TBL] [Abstract][Full Text] [Related]
11. N-(3-fluoro-4-(4-(2-methoxy or 2,3-dichlorophenyl)piperazine-1-yl)butyl)arylcarboxamides as selective dopamine D3 receptor ligands: critical role of the carboxamide linker for D3 receptor selectivity. Banala AK; Levy BA; Khatri SS; Furman CA; Roof RA; Mishra Y; Griffin SA; Sibley DR; Luedtke RR; Newman AH J Med Chem; 2011 May; 54(10):3581-94. PubMed ID: 21495689 [TBL] [Abstract][Full Text] [Related]
12. New tetrahydroisoquinoline-based D Cordone P; Namballa HK; Muniz B; Pal RK; Gallicchio E; Harding WW Bioorg Med Chem Lett; 2021 Jun; 42():128047. PubMed ID: 33882273 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity. Ananthan S; Saini SK; Zhou G; Hobrath JV; Padmalayam I; Zhai L; Bostwick JR; Antonio T; Reith ME; McDowell S; Cho E; McAleer L; Taylor M; Luedtke RR J Med Chem; 2014 Aug; 57(16):7042-60. PubMed ID: 25126833 [TBL] [Abstract][Full Text] [Related]
14. RalA employs GRK2 and β-arrestins for the filamin A-mediated regulation of trafficking and signaling of dopamine D2 and D3 receptor. Zheng M; Zhang X; Sun N; Min C; Zhang X; Kim KM Biochim Biophys Acta; 2016 Aug; 1863(8):2072-83. PubMed ID: 27188791 [TBL] [Abstract][Full Text] [Related]
15. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. Newman AH; Beuming T; Banala AK; Donthamsetti P; Pongetti K; LaBounty A; Levy B; Cao J; Michino M; Luedtke RR; Javitch JA; Shi L J Med Chem; 2012 Aug; 55(15):6689-99. PubMed ID: 22632094 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of arylpiperazine-reverse amides as biased dopamine D3 receptor ligands. Cao Y; Paudel S; Zhang X; Kim KM; Cheon SH Bioorg Med Chem; 2015 Sep; 23(17):5264-72. PubMed ID: 26278029 [TBL] [Abstract][Full Text] [Related]
17. Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor Agonist Selectivity. Zou MF; Keck TM; Kumar V; Donthamsetti P; Michino M; Burzynski C; Schweppe C; Bonifazi A; Free RB; Sibley DR; Janowsky A; Shi L; Javitch JA; Newman AH J Med Chem; 2016 Apr; 59(7):2973-88. PubMed ID: 27035329 [TBL] [Abstract][Full Text] [Related]
18. Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists. Xu W; Wang X; Tocker AM; Huang P; Reith ME; Liu-Chen LY; Smith AB; Kortagere S ACS Chem Neurosci; 2017 Mar; 8(3):486-500. PubMed ID: 27801563 [TBL] [Abstract][Full Text] [Related]
19. Opposing relationships of BMI with BOLD and dopamine D2/3 receptor binding potential in the dorsal striatum. Cosgrove KP; Veldhuizen MG; Sandiego CM; Morris ED; Small DM Synapse; 2015 Apr; 69(4):195-202. PubMed ID: 25664726 [TBL] [Abstract][Full Text] [Related]